Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr
Branded formulation business continues to perform well across domestic and export markets
Branded formulation business continues to perform well across domestic and export markets
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
The inspection was carried out from January 28 to February 1, 2025
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Subscribe To Our Newsletter & Stay Updated